RAC media coverage, page-1903

I think the videos can be structured in a couple of ways:

1. By target audience: beginner biotech investor who care about a big payoff, investors who want to understand derisked nature of bisantrene, people who know cancer patients and care about safer treatments and want to support the company,

2. By particular angle: Competition having cardioprotection (if any), size of market/ revenue/ profit potential (could refer to Triangle report), M&A/ licensing opportunities (refer to recent Aussie examples such as Neuren), rediscovered drugs and how they can be derisked opportunities (eg Keytruda), potential for accelerated approval, recent AML trial results and interest of Aussie investigators

PS: I think targeting the right kind of audience is important. Personally I would think that investors who can’t watch a 2-3 minute informational video may not be invested for a couple of years and hence not worth the effort to target and onboard them but I am sure many will consider me old fashioned (which I am).